

# Vidarbha Journal of Internal Medicine



Original Article

# Study of Clinical Spectrum of Neurological Manifestations in HIV/AIDS Seen at Tertiary Referral Hospital in India

Kiran Bhagwat<sup>1</sup>, Walmik Yegade<sup>2</sup>, Jai Inder Singh<sup>3</sup>, Ashok Meshram<sup>4</sup>, Jitesh Goel<sup>1</sup>

Departments of <sup>1</sup>Neurology, <sup>2</sup>Internal Medicine, <sup>3</sup>Nephrology, <sup>4</sup>Hematology, Command Hospital (EC), Kolkata, India.

## **ABSTRACT**

Objectives: The pandemic caused by human immunodeficiency virus (HIV) is one of the fastest growing health problems in the world today. Neurological manifestations of HIV infection and acquired immunodeficiency syndrome (AIDS) are being seen in a frequency that is parallel to the increasing number of new cases seen the world over. The World Health Organisation (WHO) estimates that 36.7 million people in the world are infected with HIV. Neurological manifestations of HIV disease can be seen in 20% of outpatients in HIV clinics and almost half of HIV patients being treated as in-patients. Of the various subtypes of HIV, subtype C is responsible for more than 50% of HIV1 infections causing rapidly growing epidemics in India. The objectives of this study were as follows: (1) To evaluate the prevalence of neurological manifestation in HIV-positive patients admitted to a tertiary referral Hospital in India. (2) To describe the neurological manifestations documented. (3) To find the possible predictors of neurological manifestations.

Material and Methods: This study was a single centre prospective cross-sectional study in which out of 200 HIV/AIDS patients, 40 patients with neurological manifestations were analysed over a period of 18 months. They were interviewed and evaluated with particular reference to neurological manifestations, and were classified using the WHO staging system.

Results: Amongst the studied population of 40 patients, 16 patients (40%) manifested as tuberculous meningitis (TBM) with or without brain  $tuber culomas, followed by seven patients (18\%) \ presented \ with peripheral \ neuropathy \ and \ six \ patients (15\%) \ presented \ with \ central \ nervous \ system (CNS)$ vasculitic or multi-infarct state. Cryptococcal meningitis was seen in five patients (12%), efavirenz-induced psychosis/seizure seen in one patient, while HIV-induced polymyositis, progressive multifocal leukoencephalopathy progressive multifocal leukoencephalopathy, acute inflammatory demylinating polyradiculoneuropathy, AIDS dementia complex and CNS toxoplasmosis were seen in one patient each respectively. One patient presented with dual opportunistic infection with coexistence of cryptococcal and tuberculous meningitis.

Conclusion: Headache with or without vomiting, seizures and altered sensorium were the most common neurological symptoms. Fundus abnormalities, meningeal signs, gait abnormalities, cranial nerve dysfunction and hemiplegia were the most common neurological signs. New-onset headache was a significant predictor of the occurrence of neurological complications. Opportunistic infections such as TBM and Cryptococcal meningitis were most commonly observed.

Keywords: Progressive multifocal leukoencephalopathy (PMLE), AIDS dementia complex (ADC), Tuberculous meningitis (TBM), Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Acquired immunodeficiency syndrome (AIDS).

#### INTRODUCTION

Human immunodeficiency virus (HIV)-1 is a neurotropic virus.[1] In a resource-limited country such as India, large populations of affected patients now have access to adequate chemoprophylaxis for opportunistic infections (OIs), allowing them to live longer. With the identification of HIV in 1983 and its proof as etiologic agent in 1984 and with the availability of sensitive and specific diagnostic tests for HIV infection, the case definition of acquired immunodeficiency syndrome (AIDS) has undergone several revisions over the years. The current Centre of Disease Control (CDC) classification system for HIV-infected adolescents and adults categorises persons

based on the clinical conditions associated with HIV and CD4 counts. Using this system, any HIV-infected individual with a CD4 count of <350/mm³ has AIDS by definition regardless of the presence of symptoms or opportunistic diseases. The pandemic caused by HIV is one of the greatest public health threats in the world today.<sup>[2]</sup> It is estimated that one million are thought to have died of the illness by December 2016, while another 36.7 million HIV-infected people were alive. Almost 1.8 million people are thought to have been infected during the previous 12 months. The majority of the disease burden remains in sub-Saharan Africa, but the number of HIV-infected people is rapidly increasing in other regions, especially in Asia and Eastern Europe.

\*Correspondingauthor: Dr. Kiran Bhagwat, Department of Neurology, Command Hospital (EC), Kolkata, India. kiranbhagwat2000@gmail.com Received: 16 February 2024 Accepted: 02 May 2024 Published: 10 July 2024 DOI: 10.25259/VJIM\_5\_2024

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. ©2023 Published by Scientific Scholar on behalf of Vidarbha Journal of HIV is predominantly transmitted sexually, but other routes of transmission include parenteral transmission - through infected blood, blood products or injecting drug use and vertical transmission from mother to child transmission, which may occur before, during or after birth. Although the complementary nature of preventing new HIV infections and treatment and care of HIV-infected individuals was recognised some time ago, only recently has it been more widely recognised that the containment of the HIV pandemic requires a global strategy which combines effective prevention with treatment and care programmes. The increased provision of HIV treatment, care and prevention services to millions of HIV-infected people have now become a HIV major policy target among national and international organisations across the world.

The hallmark HIV disease is profound immunodeficiency resulting primarily from progressive qualitative and quantitative deficiency of a subset of T lymphocytes referred to as helper T-cells or inducer T-cells. This subset of T-cells is defined phenotypically by the presence on its surface of CD4 molecule which serves as a primary cellular receptor for HIV. When the number of CD4 cells decline below a certain level, the patient is at high risk for developing a variety of opportunistic diseases particularly the infections and neoplasia that are AIDS-defining illnesses.[3] The diagnosis of HIV infection depends on the demonstration of antibodies to HIV and/or the direct determination of HIV or one of its components. The standard screening test for HIV infection is enzyme-linked immunosorbent assay (ELISA) and the most common confirmatory test is the Western blot. The CD4+ T-cell is the laboratory test considered as the best indicator of immunologic competence of patients with HIV infection.

It is now recognised that every level of the neuroaxis can be involved and at least 1/3 of the patients with advanced HIV infections will develop neurological complications during the course of their illness and in 10% of the cases, it may be first sign of the development of AIDS.[4]

Neurological manifestations related to HIV infection can be broadly classified into HIV infection, OI, neoplasia and antiretroviral therapy (ART) related. [5]

HIV estimates derived using globally comparable methods and findings from the independent Impact Assessment Study show that the National AIDS Control Programme is progressing steadily toward the objective of halting and reversing the HIV epidemic in India over the period 2012-2017. [6] Available evidence on HIV prevalence and future statistical projections shows signs of stabilisation of HIV epidemic in India at national level. Provisional estimates show that there are 21.17 lakh people living with HIV/AIDS in India by the end of 2015 with an estimated adult HIV prevalence of 0.26%.

Declining trends are noted in high prevalence states indicating possible impact of sustained programme interventions. Even the prevalence among pregnant women in the age group of 15-24 years, which is considered proxy for incidence/new infections in general population, is showing a declining trend. The overall HIV prevalence among different population groups in 2014-15 continues to portray the concentrated epidemic in India, with a very high prevalence among high-risk groups-intravenous drug users (IDU's) (9.9%), male sex with male (MSM) (7.3%), female sex workers (FSW's) (4.3%) and sexually transmitted diseases (STD's) clinic attendees (2.5%) and low prevalence among antenatal (ANC) clinic attendees (0.49%).

## MATERIAL AND METHODS

## Setting

This was a single centre non-randomised observational study between January 2012 and June 2013 on 40 out of 200 total HIV/AIDS patients in different stages of neurological manifestations seen as inpatients in a tertiary referral hospital in India. All respondents were adults, aged more than 18 years. Informed consent was taken before inclusion in the study. Those who did not give consent for the study were excluded from the study.

#### Aims

This study is designed to evaluate various spectrums of neurological manifestations seen in HIV/AIDS patients seen at a tertiary referral hospital in India.

## **Objectives**

The objectives of this study were as follows:

## **Primary**

- To evaluate the prevalence of neurological manifestation in HIV-positive patients admitted to a tertiary referral hospital.
- To describe the neurological manifestations documented.

## Secondary

- To find the possible predictors of neurological manifestations.
- To evaluate the neurological complications secondary to ART

#### Methods

The study was a prospective cross-sectional study in which out of 200 HIV patients 40 patients with neurological manifestations were analysed. Patients were selected on an in-patient basis. All patients/attendants (in case of altered mental status) were interviewed face to face and evaluated by the investigator, with particular reference to neurological manifestations. Investigations were done based on the needs of the patients after a thorough clinical evaluation. They were classified into various stages of HIV using the World Health Organisation (WHO) staging system.

A Pro forma, which is appended in the Annexure, was used for the above purpose.

#### **Tests**

HIV was confirmed by the ELISA test. Total count and differential count were performed in the laboratory using automated counting chambers and confirmed manually. CD4 counts were analysed using the flow cytometry method -FACS calibur. Other tests including plasma viral load were done as per the needs of the patients.

#### Inclusion criteria

The following criteria were included in the study:

Patient those who are HIV-positive with neurological symptoms or signs at the time of admission or developed during hospital stay.

#### Exclusion criteria

The following criteria were excluded from the study:

- HIV patients without neurological manifestations, pregnant lady patients or those who had not given consent for inclusion in study group.
- Neurological manifestations due to other established causes such as ischemic/haemorrhagic stroke.

#### **RESULTS**

Mean age in males was 37 years and in females 35 years. The females had a shorter duration of HIV illness as compared to their male counterparts. Majority of the patients were diagnosed in a symptomatic state when they presented with an OI.[7] A greater proportion of females were diagnosed with HIV in an asymptomatic state during screening, either during pregnancy or when the spouse was found to be positive.

Almost 20% of patients were diagnosed recently with their first neurological manifestations. Half of the total patients presented within one year of illness. One patient presented as long as 15 years of their illness with neurological manifestations. A major risk factor for disease acquisition was unprotected sexual intercourse in 67% of our patients. About 21% of patients gave a history of blood transfusion, while 2% of the patients gave a history of occupational exposure (needle stick injury).

Approximately 70% of our patients gave a history of smoking, followed by 65% of patients who gave a history of significant alcohol consumption (>10 drinks per week). All the patients were male.

Headache was the most common neurologic symptom seen and was often associated with vomiting. This was followed by seizures and altered sensorium [Table 1].

<b>Table1:</b> Frequency of neurological symptoms at presentations.						
Symptoms	Frequency(n)	(%)				
Headache	17	42%				
Vomiting	11	28%				
Altered Sensorium	13	33%				
Seizures	5	13%				
Impaired Judgement	2	5%				
Forgetfulness	2	5%				
Emotional outbursts	3	7%				
Impaired language	2	5%				
Hallucinations	1	3%				
Dreaming	1	2%				
Involvement of Cranial Nerve/s	9	23%				
Unilateral upper and lower limb	4	10%				
weakness						
Bilateral lower limb weakness	3	7%				
Muscle pain	2	5%				
Wasting, Fasciculations	0	-				
Limb weakness	1	2%				
Tingling and Numbness	7	18%				
Tremors	1	2%				
Ataxia	2	5%				
Bowel / Bladder symptoms	2	5%				
Impotence	3	7%				

Fundus abnormalities were the most common neurological signs documented in 23 patients. Other signs include meningeal signs, gait abnormalities, cranial nerve abnormalities and hemiplegia [Table 2].

Table 2: Various neurological signs at presentations.	
Signs	(%)
Fundus abnormality	35
Meningeal signs	30
Cranial nerve involvement	23
Paresthesia	18
Gait abnormality	15
Hemiparesis	13
Loss of consciousness	10
MMSE score less than (24/30)	9
Paraparesis	5
Cerebellar signs	5
Quadriplegia	3
Anisocoria	3
MMSE: Mini mental status examination	

The mean CD4 counts in males were 121.7/mm<sup>3</sup> and in females 119.7/mm<sup>3</sup>.

## Investigations

## Cerebrospinal fluid (CSF) analysis [Figure 1]

CSF analysis<sup>[8-10]</sup> was diagnostic in 22 (84.61%) patients out of 26 patients who underwent CSF analysis and tuberculosis followed cryptococcus was most frequent opportunistic infection noted amongst the studied population.




Figure 1: Cerebrospinal fluid (CSF) analysis. [TBM: tuberculous meningitis].

Computed tomography (CT)/Magnetic resonance imaging (MRI) brain findings [Figure 2]




Figure 2: Computed tomography/magnetic resonance imaging brain findings among the studied patients. [SOLs: space occupying lesions].

Cerebral edema was the most common brain imaging finding noted in 23% of patients, followed by space occupying lesions (SOLs)/basal exudates seen in 15% of patients, multiple infarcts were seen in 13% of patients, cerebral atrophy was noticed in 7% of patients, periventricular hyperintensity seen in 5% and hydrocephalus was seen in 5% of our patients. In 19% of patients, imaging was normal. Most of the spaceoccupying lesions detected were tuberculomas in disseminated tuberculosis patients, while one patient had toxoplasmosis.

## Neurological diagnosis

neurological Varied spectrum of manifestations [Figure 3] was noted in 82% of the studied population and all the patients those had central nervous system (CNS)




Figure 3: Spectrum of various neurological manifestations amongst human immunodeficiency virus/acquired immunodeficiency syndrome patients. [TBM: tuberculous meningitis, CVA: cerebrovascular accident, CNS: central nervous system, AIDP: inflammatory demyelinating polyradiculoneuropathy, ADC: AIDS dementia complex, PMLE: progressive multifocal leukoencephalopathy]. The numbers in bracket on the X-axis represent number of cases.

manifestations were in WHO stage 4. Fifty-five percent of the patients were on ART and the mean duration of ART was 19.84 months. Some of the patients were on the second or third line of ART. More than 25% of patients were detected recently. The CD4 counts showed better correlation with the occurrence of neurological manifestations.

## Type of ART

Among all the patients were not (45%) on ART, while those patients who were on (55%) ART were as follows [Figure 4]:

- on 1st line ART-15%,
- 2<sup>nd</sup> line ART-22%
- 3rd line ART-18%




Figure 4: Type of antiretroviral therapy. [TDF: tenofovir disoproxil fumarate, 3TC: lamivudine, EFZ: efavirenz, d4T: stavudine, NVF: nevirapine, TNF: tenofovir, FTC: emtricitabine, DAR+R: darunavir+ ritonavir].

## Graphical correlation between CD4 count and neurological manifestations

Association between CD 4 count and neurological complications [Figure 5].




Figure 5: Associations between CD4 count and neurological complications. [P. neuropathy: peripheral neuropathy, TBM + crypto M.: tuberculous meningitis + cryptococcal meningitis, EFZ: efavirenz, CNS: central nervous system, PMLE: progressive multifocal leukoencephalopathy, ADC: AIDS dementia complex, AIDP: acute inflammatory demyelinating polyradiculoneuropathy].

## **DISCUSSION**

Out of the total 200 HIV patients (outpatients + in-patients department) who came to our centre, neurological problem was detected in 40 patients. Headache with or without vomiting, seizures and altered sensorium were the most common neurological symptoms.[11-13] Fundus abnormalities, meningeal signs, gait abnormalities, cranial nerve dysfunction and hemiplegia were the most common neurological signs. Newonset headache was a significant predictor of the occurrence of neurological complications. CSF examination revealed a positive diagnosis in the majority of the patients who underwent the test. OIs remained the most common problems detected, which included tuberculous meningitis (TBM), Cryptococcal meningitis, a combination of both and viral meningitis.

HIV-related neurological problems documented (6 out of 40) included AIDS dementia complex,[14,15-17] neuropathy. progressive multifocal leukoencephalopathy, central nervous system vasculitis and seizures due to efavirenz.[18] One patient had coexistent TBM and cryptococcal meningitis, emphasising the need for clinicians to be aware that multiple OIs can exist in the same system in these patients.

Patients in WHO stage 4 were at the maximum risk for neurological complications. CD4 counts were significantly lower in patients with neurological complications, and most of the neurological manifestations and all the OIs were documented in the patients with CD4 counts below 350/mm<sup>3</sup>. Neurological complications did not show any correlation with the patients being on ART or with the duration of ART. [19,20] The possible reasons for this include differing baseline CD4 counts at the start of ART and treatment failure in a subset of patients.

#### **CONCLUSION**

Headache with or without projectile vomiting, altered sensorium, and seizure were the commonest symptoms, whereas fundus abnormalities, including papilledema, cranial nerve deficit, signs of meningeal irritation, and focal neuro-deficit in the form of hemiplegia were the commonest signs of neuro-axial involvement. New onset headache was a significant predictor of the occurrence of neurological complications. Amongst all the opportunistic infections (OI's), tuberculosis, followed by cryptococcal, was the leading infectious etiology. Hence, we should have a low threshold in identifying and prompt treatment of such opportunistic infections for a better outcome in such a subset of patients.

## Acknowledgments

The author sincerely thanks to all his colleagues, respected teachers, family members for their constant support, motivation and guidance.

## **Ethical approval**

The research/study had been approved by the Institutional Review Board at Medicity Hospitals, Hyderabad (Telangana), vide reference number 111-12128-111-100110, dated 08 September 2011.

## Declaration of patient consent

The auther certifies that he has obtained all appropriate patient consent.

## Financial support and sponsorship

Nil.

#### **Conflicts of interest**

There are no conflicts of interest.

## Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

#### REFERENCES

- Fauci AS, Lane HC. Human Immunodeficiency Virus disease: AIDS and Related Disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19th ed. New York: McGraw-Hill; 2015.
- Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS Epidemic

- Update: May 2016, UNAIDS/04.45E. Geneva, Switzerland: UNAIDS/WHO; 2016.
- Picot P, Ozawkie D, Turkmen T. HIV/AIDS Prevention and Treatment. Lancet 2002;360:86-9.
- Snider WD, Simpson DM, Nielsen S, Gold JW, Metrical CE, Posner JB. Neurological Complications of Acquired Immune Deficiency Syndrome: Analysis of 50 Patients. Ann Neural 1983;14:403-18.
- Levy RM, Bresden DE, Rosenblum ML. Neurological Manifestations of the Acquired Immune Deficiency Syndrome: Experience at UCSF and Review of the Literature. J Neurosurgeon 1985;62:475-95.
- National AIDS Control Organization HIV Sentinel Surveillance Report - (HSS -2017) Executive Summary; 2017.
- Gendelman HE, Lipton SA, Epstein L, Swindells S, editors. The Neurology of AIDS. New York: Chapman and Hall; 1998.
- Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN. Spectrum of Cerebrospinal Fluid in Various Stages of Human Immunodeficiency Virus Infection. Arch Neurol 1988;45:954-8.
- Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early Penetration of the Blood Brain Barrier by HIV. Neurology 1988;38:9-14.
- 10. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. 2<sup>nd</sup> ed. Philadelphia, PA: W.B. Saunders; 1992.
- 11. Carne CA, Tedder RS, Smith A, Sutherland S, Elkington SG, Daly HM, et al. Acute Encephalopathy Coincident with Seroconversion for Anti- HTLV-III. Lancet 1985;2:1206-8.
- 12. McArthur JC. Neurologic Manifestations of AIDS. Medicine (Baltimore) 1987;66:407-37.

- 13. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and Their Receptors in the Central Nervous System. Front Neuroendocrinol 2001;22:147-84.
- 14. Glass JD, Wesslingh SL. Viral Load in HIV-Associated Dementia. Ann Neurol 1998;44:150-1.
- 15. Nath A. Pathobiology of Human Immunodeficiency Virus Dementia. Semin Neurol 1999;19:113-27.
- 16. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS Dementia Complex in the Era of Highly Active Antiretroviral Therapy. AIDS 1999;13:1249-53.
- 17. Clinical Confirmation of the American Academy of Neurology Algorithm for HIV-1 Associated Cognitive/Motor Disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 1996;47:1247-53.
- 18. McClernon DR, Lanier R, Gartner S, Feaser P, Pardo CA, St Clair M, et al. HIV in the Brain: RNA Levels and Patterns of Zidovudine Resistance. Neurology 2001;57:1396-401.
- Wafaa M, El-Sadr, Homes CB, Mugyenyi P, Thirumurthy H, et al. Scale -up of HIV Treatment Through PEPFAR:A Historic public health Achievement ,J Acquir Immune Defic Syndr 2012;60:S96-S104.
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available from: https:// www.aidsinfo.nih.gov/guidelines/adult/AA\_030204.pdf4 [Last accessed on 2013 May 04].

How to cite this article: Bhagwat K, Yegade W, Singh J, Meshram A, Goel J. Study of Clinical Spectrum of Neurological Manifestations in HIV/ AIDS Seen at Tertiary Referral Hospital in India. Vidarbha J Intern Med. 2023;33:82-9. doi: 10.25259/VJIM\_5\_2024

ANNEXURE Study Pro forma:			17. I	ocial disinhibitio mpaired Languag /isual/auditory ha	ge	
Name	Age	Sex	19. I	Disturbed body in	nage	
IP/OP No:	Ward-		Exam	ination:		
DOA://.	DOD://.		Pulse	-/min,		Temp-
Marital status:			B.P -/	mm Hg,		•
Address:						
Presenting Complaints:		Resp Rate-/min Pallor/Icterus/Cyanosis/Clubbing/Lymphadenopathy/oedema				
2				•		ny/oedema
1. 2.				ocutaneous mark	ers-	
3.			CNS	examination:		
History of presenting comp	olaints:		Higher Mental Functions  Cranial nerves  C.N.(I,II) –			
Past History						
Date of diagnosis:	Duration of H	HIV.				
•	ž	11 7.		us examination:		
Fresh de novo detected pat			<ul><li>C.N.(III.IV &amp; VI)-</li><li>C.N.(V)-</li></ul>			
Already diagnosed patient				C.N.(VII,VIII)-		
Already diagnosed & recei	ving HAART Patient-Y	ℓ/N.		C.N.(IX,X)		
How Diagnosed:				C.N.(XI) C.N.(XII)-		
<ol> <li>Routine 2. OI 3. Intercurrent illness 4. Unrelated</li> <li>History of high risk behaviour: Y/N</li> <li>History of blood transfusion: Y/N</li> </ol>						
		Motor system:-				
	tional exposure: Y/N		1. N	Nutrition-	Dight	Left
Tuberculosis: Y/N				-	Right	Leit
<ul> <li>IV drug abuse: Y/</li> </ul>	N		2.	Power-	i. UL- ii. LL-	
• Smoking: Y/N				m.		
<ul><li>Alcohol: Y/N</li><li>CVA: Y/N</li></ul>			3.	Tone-	i. UL- ii. LL-	
• Seizure disorder:	Y/N		C1		II, LL	
<ul> <li>Diabetes: Y/N</li> </ul>			Clon			
• Hypertension: Y/	Ŋ		4.	Reflexs-	I Cornea & Conju. ii Cremaster reflex	
Neurological History:					iii abdominal reflex	
1. Headache					iv bicep reflex	
<ul><li>2. Vomiting</li><li>3. Generalised weakness</li></ul>					v supinator reflex	
4. Seizures					vi tricep reflex Viii knee reflex	
5. Altered Mental Status					vii ankle reflex	
6. Numbness/Tingling	1				ix Ankle jerk	
<ul><li>7. Weakness Proximal/di</li><li>8. Wasting, fasciculation</li></ul>			5. Ser	nsory system-	•	
9. History s/o cranial ner			pain & temp-			
10. Mono/hemi/quadripa:			joint sense, vibration, pressure-			
11. Bowel/bladder inconti			C	rude touch-		
12. Impotence			6. Ce	rebellar Signs:-		
<ul><li>13. Impaired memory/jud</li><li>14. Altered personality</li></ul>	gment		7. Inv	oluntary movem	ents	
15. Fine tempersonanty			0.0.			

15. Emotional outbursts

8. Spine examination:-

9. Gait: -

Respiratory System:-

Cardiovascular System:-

Abdomen Examination: -

Investigations:-

Complete blood count, liver and renal function tests, serum

electrolytes, and random blood sugar.

Chest X-Ray-

USG Abdomen:

CT Scan/MRI Brain-

CSF Analysis-

TLC-1.

Sugar-2. Protein-

GM/AFB stain-

TB PCR-

CRYPTO Ag-

Fungus-

Others-

Electrophysiological studies-

1. Electroencephalogram (EEG)

2. Nerve Conduction study (NCS)

CD4 Counts:

Others

On ART: Y/N

Duration of ART:

What ART:

DLC-

WHO staging-Final Diagnosis:

WHO Classification:

Neurological Diagnosis: